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Neutralization of Japanese 
Encephalitis Virus by heme-
induced broadly reactive human 
monoclonal antibody
Nimesh Gupta1,2,3,†, Mélissanne de Wispelaere4, Maxime Lecerf1,2,3, Manjula Kalia5, 
Tobias Scheel6, Sudhanshu Vrati5, Claudia Berek6, Srinivas V. Kaveri1,2,3, Philippe Desprès4,7, 
Sébastien Lacroix-Desmazes1,2,3 & Jordan D. Dimitrov1,2,3
Geographical expansion and re-emerging new genotypes of the Japanese encephalitis virus (JEV) 
require the development of novel therapeutic approaches. Here, we studied a non-conventional 
approach for antibody therapy and show that, upon exposure to heme, a fraction of natural human 
immunoglobulins acquires high-affinity reactivity with the antigenic domain-III of JEV E glycoprotein. 
These JEV-reactive antibodies exhibited neutralizing activity against recently dominant JEV 
genotypes. This study opens new therapeutic options for Japanese encephalitis.
The appearance of new highly virulent genotypes of JEV is a growing cause of concern1,2. Japanese 
encephalitis (JE) is a vaccine-preventable disease, however, due to its enzootic transmission it can never 
be eradicated from the natural environment. Therefore, even though vaccination can reduce its incidence, 
effective antiviral therapy is a necessity to supplement existing strategies for controlling the disease3.
Following an infected mosquito bite, the virus replicates at low levels in the spleen and spreads by 
haematogenous route to other parts of the body including the central nervous system. In this early 
phase, the immune response efficiency determines disease outcome4. Although both the humoral and 
cellular arms of the immune system are involved in immunity to JEV, their relative contribution is not 
well understood. Importantly, failure to efficiently produce virus-specific antibodies (Abs) is associated 
with an increased likelihood of developing severe disease5. Indeed, the passive transfer of neutralizing 
Abs was shown to protect mice against JEV infection6–10.
In animals, the administration of neutralizing Abs is mostly efficient when delivered at the same 
time as the virus challenge. In humans, JE has an incubation period of 5 to 15 days and non-specific 
symptoms may last for up to 6 days. It is therefore uncertain whether the mere targeting of the virus 
using JEV-specific Abs would be therapeutically efficient. In fact, an intravenous IgG preparation (IVIg) 
that is not hyper-immune to JEV showed therapeutic benefits in the recovery from JE11. The protection 
conferred by IVIg was attributed to its anti-inflammatory potential12. Indeed, hyper-inflammation at the 
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periphery or in the brain plays a decisive role in JEV pathogenesis13–16. Hence, the ideal Ab candidate for 
passive therapy should target both the virus as well as the associated hyper-inflammation.
In all healthy individuals a fraction of Abs can be detected that acquire novel antigen-binding specifi-
cities or polyreactivity upon in vitro or in vivo exposure to redox agents, including the ubiquitous cofac-
tor molecule heme17–19. Notably, heme was found to confer novel binding specificities to Abs without 
influencing binding to their cognate antigen19,20. Importantly, the contact of Abs with redox agents also 
results in a substantial increase of their anti-inflammatory potential. Thus, heme or ferrous ions exposed 
human immunoglobulins considerably improved the survival in mouse model of bacterial sepsis and 
inhibited the development of autoimmune inflammation of insulin islet cells in mice18,21. Therefore, Abs 
with inducible polyreactivity may represent an appropriate therapeutic tool for JEV-mediated disease.
Results and Discussion
To test this hypothesis, the frequency of Abs that acquire specificity to JEV proteins upon exposure to 
heme in the human immune repertoire was determined. We analyzed a panel of 97 human recombinant 
monoclonal IgG1, cloned from different subpopulations of B cells isolated from the synovial tissue of 
patients with rheumatoid arthritis22. Following exposure to heme, approximately 9% of Abs acquired 
binding specificity to the JEV envelope (E) protein (Fig. 1A,B). Interestingly, while analyzing the same 
repertoire, we observed that 24% of the Abs acquire reactivity to HIV-1 gp12023. Among JEV E binding 
Abs all gained reactivity to gp120 as well. Future studies may decipher whether this difference in the fre-
quencies of heme-induced Abs is due to the different mechanisms underlying heme-induced specificity, 
or differential characteristics of the viral antigens. Further analyses of the characteristics of the variable 
region sequences of the immunoglobulins revealed that Abs, that acquired reactivity towards JEV E 
upon heme exposure have significantly lower number of somatic mutations (Fisher’s exact test P = 0.01) 
(Fig. 1C). Most of the Abs gaining reactivity to JEV E protein originated from naïve B cells (comparison 
of frequency of plasma and naïve B cells by Fisher’s exact test P = 0.04) and thus expressed IgM as orig-
inal isotype (Fig. 1D). The gene families encoding the variable regions genes, the length of CDR3s and 
the prevalence of different amino acids in the CDRs of the light and heavy chains of Abs were similar 
whether Abs acquired binding to JEV E or not upon exposure to heme (Fig. S1).
To delineate the mechanistic and functional understanding of induced JEV recognition, we focused 
on a monoclonal IgG1 (mAb21) that demonstrated high sensitivity to heme-induced specificity for JEV 
(Fig.  1b). First, mAb21 (1 μ M) was exposed to hematin (5 μ M) and the binding to JEV E and to the 
recombinant domain-III24 of JEV E (EDIII, Fig.  2A) was studied. Kinetic analyses demonstrated that 
exposure of initially non-reactive mAb21 to heme resulted in acquisition of binding affinity in the nano-
molar range to both, JEV E and EDIII (Table  1). As a reference, the JEV E-reactive mouse monoclo-
nal Ab 4G2 (ATCC HB-112) also displayed affinity in nanomolar range to JEV E (Fig. S2). Moreover, 
thermodynamic analyses revealed that recognition of JEV E and EDIII by heme-exposed mAb21 is an 
entropy-driven process with minimal contribution of enthalpy (Fig. 2B). The negative values of associa-
tion entropy imply that interaction of the heme-exposed mAb21 with both JEV proteins is accompanied 
by structural reorganizations or by changes in the solvent structure (Fig.  2C). For further biological 
characterizations, we also studied a therapeutic monoclonal IgG1 (Rituxan; Rtx) that has already been 
described to acquire substantial antigen-binding polyreactivity after exposure to heme25. The thermody-
namic mechanism of recognition of JEV proteins by both heme-exposed Rtx and mAb21 were similar 
(Table 1, Fig. S3A).
Finally, we evaluated the functional efficacy of the heme-induced JEV-reactive Abs in a focus-reduction 
neutralization test (FRNT) on BHK-21 cells. First Rtx (33.5 μ M) was exposed to hematin (50 μ M). The 
neutralization potency was then assayed using 3-fold serial dilutions of the heme-exposed Ab. The 
JEV-reactive Ab demonstrated a dose-dependent neutralization of JEV GIII with an absolute IC50 of 
1.33 ± 0.12 μ M (heme-treated over native: P = 0.004 at 6.7 μ M; P = 0.003 at 2.2 μ M; Fig.  3A). It also 
demonstrated broad neutralization capacity since the induced JEV-reactive Ab also neutralized the highly 
pathogenic and dominating JEV genotypes GI with an absolute IC50 of 1.36 ± 0.09 μ M (heme-treated over 
native: P = 0.009 at 6.7 μ M; P = 0.004 at 2.2 μ M; Fig. 3B) and GV26 with an absolute IC50 of 0.52 ± 0.04 μ M 
(heme-treated over native: P = 0.009 at 6.7 μ M; P = 0.01 at 2.2 μ M; P = 0.01 at 0.7 μ M; Fig. 3C). Whether 
this broad reactivity is the result of higher epitope accessibility on the viron envelope or due to the Ab 
docking on particular epitope in EDIII domain remains to be explored27. Controls that consisted of heme 
alone or heme-exposed albumin had no neutralizing effect on the virus infectivity, indicating that heme 
alone does not have direct effects on reducing virus infectivity in our experimental setup.
Our study highlights the prevalence and the binding mechanism of heme-inducible JEV reactive Abs 
in the human immune repertoire. Furthermore, our data suggest the biological potency of these Abs in 
neutralizing distinct JEV genotypes. Thus, our approach may be of value in producing therapeutic Abs 
of new defined specificity from the normal human immune repertoire. Although previously validated in 
animal models, the anti-inflammatory effects of heme-inducible antibody remains to be explored in JE 
infection model. Moreover, simultaneous to these validations, conferring the anti-inflammatory potential 
to existing JEV-neutralizing Abs by exposure to redox agent will also be appealing to identify a novel 
candidate therapy. Additional in depth investigations in suitable animal models are thus warranted to 
establish the value of our approach.
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Figure 1. Repertoire analyses of prevalence, origin and characteristics of heme-induced JEV binding 
Abs. (A) Representative data obtained by immunoblot analysis of interaction of different native and 
heme-exposed human Abs with immobilized JEV E protein. The JEV protein was directly immobilized 
on the surface of nitrocellulose membrane. Each monoclonal Ab was diluted to 20 μ g/ml and incubated 
with the immobilized JEV E. As controls, native and heme-exposed pooled human IgG (IVIg) were used. 
(B) Binding intensity of native and heme-exposed human IgG1 to JEV E. The plot depicts the reactivity 
to JEV E of 97 human monoclonal IgG1 Abs. Each point represents the binding intensity of a particular 
native (blue circles) and heme-treated (red circles) Ab. Binding intensity were calculated by densitometric 
analyses of immunoblots after subtraction of background binding to nitrocellulose membranes. The 
dashed line, defined by the sum of the average binding intensity of all native Abs plus three standard 
deviations, shows the threshold of positivity. The pie graph depicts the fraction of Abs that acquires 
JEV E specificity after heme exposure (full area), and the fraction that displays no change in reactivity 
(empty area). (C) Frequency distribution analyses of number of somatic mutations in VH regions of Abs that 
gain JEV E reactivity and Abs insensitive to heme exposure. The Fisher’s exact test was applied to evaluate 
the statistical significance of the frequency distributions. (D) The pie graphs depict the fraction of B cell 
subpopulations or the distribution of percentages of original B cell receptor isotype from heme insensitive (left 
pie chart) or sensitive (right pie chart) Abs. Statistical significance was assessed by using Fisher’s exact test.
www.nature.com/scientificreports/
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Figure 2. Kinetic and thermodynamic analyses of interaction of heme-exposed human IgG1 (mAb21) 
with JEV E and EDIII proteins. (A) Real-time interaction profiles of binding of native or heme-exposed 
human monoclonal IgG1, mAb21 to immobilized recombinant JEV E and EDIII proteins. The real-time 
interaction profiles obtained after injection of native mAb21, diluted to 500 nM are presented in the 
left panels. The binding profiles of heme-exposed mAb21 at 500, 250, 125, 62.5, 31.25, 15.63, 7.81, and 
3.90 nM are presented on the right panels. The binding analyses were performed at 25 °C. The graphs show 
experimentally determined binding curves (black lines) and curves generated by globally fitting the data by 
BIA evaluation software (red line). The estimated kinetic parameters are presented on Table 1.  
(B) Arrhenius plots showing the natural logarithm values of association and dissociation rate constants 
of the heme-sensitive mAb21 obtained after interaction with JEV E (open circles) and JEV EDIII (filled 
circles) as a function of reciprocal values of temperature (in Kelvins). To generate these plots the kinetic rate 
constants were determined by global analysis of sensorgrams generated after evaluation of binding kinetics 
of the heme-exposed mAb21 with immobilized JEV proteins at varying temperatures (10, 15, 20, 25, 30, and 
35 °C). Linear regression analyses were applied to obtain the slopes of the temperature dependency.  
(C) Association, dissociation and equilibrium thermodynamic parameters of binding of heme-exposed 
mAb21 to JEV E and EDIII. Changes in the enthalpy, entropy and free energy during different phases of 
the interaction of heme-exposed mAb21 with JEV E (white bars) and EDIII (black bars) are depicted. The 
changes in non-equilibrium thermodynamic parameters were evaluated by applying Eyring’s analyses on the 
data from Arrhenius plots.
www.nature.com/scientificreports/
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Methods
Recombinant proteins and antibodies. The domain III (EDIII) of JEV envelope protein cloned 
from an Indian strain (Vellore P20778) of JEV genotype III was synthesized in E.coli as explained else-
where24. The recombinant envelope (E) protein (MBS143155) was originally cloned from JEV genotype 
III (Kamiyama strain) and obtained commercially from MyBioSource, San Diego, CA, USA.
Details about the generation of the repertoire of human monoclonal IgG1 antibodies were provided 
elsewhere22,28. Briefly, the variable genes encoding the immunoglobulin heavy and light chains were 
amplified from different B cells subpopulations by single-cell PCR from synovial tissue of rheumatoid 
arthritis patients, cloned in PUC19 vector containing the genes encoding the constant Fc-γ 1 or  λ /κ 
chains, respectively, and expressed using HEK293. Although the panel of antibodies was generated from 
patients with autoimmune disease, studied antibodies did not expressed biased tendency for binding to 
self-antigens. In some cases therapeutic humanized IgG1 antibody Rituxan (Roche, Basel Switzerland) 
was used.
Reagents. Stock solutions of oxidized heme b (ferriprotoporphyrin IX) were prepared by dissolv-
ing hemin (Fluka, St. Louis, USA) in 0.05N solution of NaOH. The heme stock solution was kept at 
4 °C. The treatment of immunoglobulins was always performed with freshly prepared heme, at dim light 
conditions.
ka × 104 mol−1 s−1 kd × 10−3 s−1 KD, nM ΔH kJ mol−1 TΔS kJ mol−1 ΔG kJ mol−1
mAb21-JEV E 1.22 ± 0.10 2.93 ± 0.22 240 − 2.0 35.8 − 37.8
mAb21-JEV EDIII 1.81 ± 0.04 2.58 ± 0.07 142 6.6 45.6 − 39.1
Rtx-JEV E 1.05 ± 0.01 3.52 ± 0.12 335 16.5 53.5 − 37.0
Rtx-JEV EDIII 0.83 ± 0.01 3.63 ± 0.10 435 4.7 41.0 − 36.3
Table 1.  Kinetic and equilibrium thermodynamic parameters of interaction of heme exposed human 
IgG1 Abs with JEV. Values of the kinetic rate constants (ka and kd) and equilibrium constants (KA and 
KD) ± SD obtained by global analyses of sensorgrams obtained after injection of heme-exposed mAb21 and 
Rtx (3.9 to 500 nM) on sensor chip with immobilized JEV E and JEV EDIII. The presented values of the 
binding kinetics were obtained at 25 °C.
Figure 3. In vitro neutralization of JEV by heme-treated human monoclonal IgG1. Neutralization 
potential of JEV-reactive heme-exposed IgG1 (Rtx) was accessed on distinct genotypes of JEV selected 
on the basis of their recent circulation in Southeast Asia. Neutralization titrations by focus-reduction 
neutralization test (FRNT) using either heme-treated or native Rtx are shown. (A) FRNT on a genotype 
III strain (JEV-RP-9)29 (B) FRNT on a chimeric virus that express the structural proteins of a genotype I 
strain (CNS769_Laos_2009)30 and the nonstructural proteins of a genotype III strain (JEV-RP-9). (C) FRNT 
on a genotype V strain (JEV-XZ0934)29. The Y-axes depict the percent neutralization that was calculated 
using the formula: 100 × (1-FFU of treatment/FFU of control). Results are depicted as means ± SEM of 
two independent experiments performed in duplicate for each concentration. Statistical significance of 
the differences between heme-treated or native IgG1 was assessed at each concentration using two-tailed 
unpaired Student’s t-test. ns: non-significant.
www.nature.com/scientificreports/
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Screening of repertoire of human IgG1 for gain of reactivity to JEV E protein after exposure 
to heme. JEV E protein was diluted to 20 μ g/mL in PBS (pH 7.4) and immobilized on nitrocellulose 
membranes using 28 channel Miniblot system (Immunetics, Boston, USA). The nitrocellulose membrane 
was incubated overnight at 4 °C. After immobilization, the membranes were blocked by incubation at 
25 °C for 1 hour in TBS buffer containing 0.1% of Tween-20. After blocking the membranes were again 
mounted in Miniblot apparatus in a direction perpendicular to one used for immobilization of the pro-
teins. Recombinant human antibodies were exposed at a 40 μ g/mL concentration, either with hemin sol-
ubilized in 0.05N NaOH or with vehicle only. The antibodies were treated with final heme concentration 
of 20 μ M. After a 30 min incubation on ice, heme-treated and native recombinant antibodies were diluted 
in TBS containing 0.1% Tween 20 (TBS-T) to final concentration of 20 μ g/ml and incubated for one 
hour on the membrane containing immobilized JEV E protein. As a positive control, 10 μ M (1.5 mg/ml) 
pooled human IgG (IVIg) was treated with hemin (20 μ M) and incubated with immobilized proteins 
at final IgG concentration of 0.05 μ M (7.5 μ g/ml) in TBS-T. After washing for one-hour membrane 
was incubated with anti-human IgG antibody conjugated with HRP, clone JDC-10 (Southern Biotech, 
Birmingham, Alabama, USA). Immunoreactivities were revealed by using Pierce ECL western blotting 
substrate (Thermo Scientific, Rockford, USA) and chemiluminescence signal was recorded on multipur-
pose film (GE Healthcare, Little Chalfont, UK).
Intensities of spots obtained at the intersections of JEV E protein and antibodies-loaded channels 
were evaluated by densitometry using ChemiCapt/Bio1D software (Vilber Lormat, Torcy, France). The 
background signal obtained after incubation of studied antibodies with nitrocellulose membrane alone 
was always subtracted from signal obtained in the presence of immobilized protein. Values were normal-
ized to controls present on each membrane to account for variations in exposure times. To identify the 
antibodies that gain significant binding to JEV E proteins after exposure to heme, values of the binding 
intensity of each antibody before and after heme exposure were plotted. A threshold that distinguishes 
heme-sensitive from non-sensitive antibodies was defined as the average index of binding of all native 
antibodies plus three standard deviations.
Evaluation of binding kinetics. The kinetics of interaction of human monoclonal antibodies with 
JEV E and EDIII proteins was measured by surface plasmon resonance-based technique (BIAcore 2000, 
Biacore, GE Healthcare).
The proteins from JE virus were immobilized on a research grade CM5 sensor chip using 
amino-coupling kit (Biacore). In brief, JEV E and EDIII were diluted in 5 mM maleic acid (pH 3.85) to 
10 μ g/ml and injected over activated sensor surface for 7 min. HBS-EP (10 mM HEPES, pH 7.4 150 mM 
NaCl, 3 mM EDTA and 0.005% Polysorbat-20) was used as a running buffer. All samples during kinetics 
measurements were diluted in this buffer, as well.
Two-fold dilutions of heme-exposed human IgG1 antibodies (Ab21 and Rtx) (500–0.976 nM) were 
injected at flow rate of 20 μ l/min for 360 sec. After following the dissociation, the regeneration of the 
binding surface was performed by 30 seconds exposure of the sensor surface to solution of 0.05 M gly-
cine pH 12, 0.15% Triton X-100, followed by 30 sec exposure to 5M urea solution. The estimation of 
the kinetic constants of the interaction was done by BIAevaluation version 4.1 software (Biacore). The 
binding signal to the surface of the control (uncoated) flow cell was subtracted from the binding to flow 
cells coated with JEV proteins. Kinetics analyses of the sensorograms were performed by global analysis 
of the real-time binding curves data using the Langmuir binding model with a correction for drifting 
base-line, included in the software.
Calculation of binding thermodynamics of monoclonal Abs to JEV proteins. Eyring’s analyses 
were used for calculation of the non-equilibrium thermodynamics, of the interactions of JEV envelope 
proteins with human antibodies exposed to heme. Kinetic measurements, as described above, were per-
formed at 15, 20, 25, 30, and 35 °C. The reciprocal values of the temperatures in Kelvin degrees ver-
sus natural logarithm of kinetic rate constants were plotted to build Arrhenius plots. The slopes of the 
Arrhenius plots were calculated by using a linear regression analysis of the experimental kinetic data by 
using GraphPad Prism version 5 (GraphPad Prism Inc.) and substituted in the equations-
= − × , ( )Ea slope R 1
where the “slope” is equal to ∂ln(ka/d/∂(1/T),
Ea is the activation energy. The changes of enthalpy, entropy and Gibbs free energy, characterizing 
the association or dissociation of heme-exposed antibodies were evaluated using the following equations:
∆ = − ( )‡H Ea RT 2
( )/ = −∆ / + ∆ / + ( ′/ ) ( )/ ‡ ‡H S R hln k T RT ln k 3a d
∆ = ∆ − ∆ ( )‡ ‡ ‡G H ST 4
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where T is the temperature in Kelvin, k′ is the Boltzman constant and h is the Planck’s constant.
The equilibrium values of the thermodynamic parameters were calculated using the equations:
∆ = ∆ −∆ ( )G G G 5eq association dissociation
∆ = ∆ −∆ ( )H H H 6eq association dissociation
∆ = ∆ − ∆ ( )S S ST T T 7eq association dissociation
All thermodynamic parameters were determined at reference temperature of 25 °C (298.15 K).
Focus-Reduction Neutralization Test (FRNT). The monoclonal IgG1 (Rtx) was treated with the 
final heme concentration of 50 μ M. FRNT was then performed with 3-fold serially diluted antibody, 
either heme-treated or native, incubated with approximately 50 focus forming unit (FFU) of respective 
virus to a 1:1 ratio at 37 °C for 1 hr. The reaction mixture was then used to infect BHK-21 cells for 1 hr 
at 37 °C with gentle shaking. The monolayer was then washed with PBS and overlaid with the overlay 
medium (1.25% methyl cellulose, 2% FBS in DMEM) for 36 hr. Foci of infected cells for each condition 
were detected after methanol fixation of the cell monolayer and immunostaining with an anti-JEV E anti-
body (4G2). The percent neutralization was calculated using the formula: 100 × (1-FFU of treatment/FFU 
of control) and the IC50 values were obtained by non-linear regression analysis with an equation of log 
(inhibitor) vs. normalized response in variable slope.
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